GlaxoSmithKline Pharmaceuticals Ltd Q1FY22 consolidated net profit climbs to Rs. 121.08 crores

GLAXOSMITHKLINE PHARMACEUTICALS LTD. has reported financial results for the period ended June 30, 2021.

Financial Results (Q1 FY 2021-22) - QoQ Comparison

The company has reported total income of Rs.821.72 crores during the period ended June 30, 2021 as compared to Rs.843.35 crores during the period ended March 31, 2021.

The company has posted net profit / (loss) of Rs.121.08 crores for the period ended June 30, 2021 as against net profit / (loss) of Rs.14.33 crores for the period ended March 31, 2021.

The company has reported EPS of Rs.7.15 for the period ended June 30, 2021 as compared to Rs.0.85 for the period ended March 31, 2021.

Financials	Q1 FY2021-22	Q4 FY20-21	% Change
Total Income	₹ 821.72 crs	₹ 843.35 crs	-2.56%
Net Profit	₹ 121.08 crs	₹ 14.33 crs	744.94%
EPS	₹ 7.15	₹ 0.85	741.18%

Financial Results (Q1 FY 2021-22) - YoY Comparison

The company has reported total income of Rs.821.72 crores during the period ended June 30, 2021 as compared to Rs.706.51 crores during the period ended June 30, 2020.

The company has posted net profit / (loss) of Rs.121.08 crores for the period ended June 30, 2021 as against net profit / (loss) of Rs.110.83 crores for the period ended June 30, 2020.

The company has reported EPS of Rs.7.15 for the period ended June 30, 2021 as compared to Rs.6.54 for the period ended June 30, 2020.

Financials	Q1 FY2021-22	Q1 FY2020-21	% Change
Total Income	₹ 821.72 crs	₹ 706.51 crs	16.31%
Net Profit	₹ 121.08 crs	₹ 110.83 crs	9.25%
EPS	₹ 7.15	₹ 6.54	9.33%

Commenting on the results, Sridhar Venkatesh, Managing Director, GlaxoSmithKline Pharmaceuticals Limited, said, "We continue to show remarkable resilience and deliver growth despite the headwinds caused by the COVID-19 pandemic. Our pharmaceutical manufacturing team worked round the clock to fulfill significantly increased demand for our key brands, especially for Ca/pol (paracetamol). This effort ensured that patients continued to have access to this important medication during the pandemic. While our vaccines business was impacted due to low vaccination rates, many of our key brands witnessed strong growth fuelled by disciplined execution, enhanced digital capabilities and agility in the market resulting in market share gains."

Shares of GLAXOSMITHKLINE PHARMACEUTICALS LTD. was last trading in BSE at Rs. 1731 as compared to the previous close of Rs. 1681.7. The total number of shares traded during the day was 15769 in over 2337 trades.

The stock hit an intraday high of Rs. 1744 and intraday low of 1673.85. The net turnover during the day was Rs. 26990565.

Source : Equity Bulls

Keywords